Merck

AbbVie's Humira, Merck's Keytruda and more: The top 10 drugs of 2024
Fierce Pharma
Fri, 06/8/18 - 09:48 am
Humira
AbbVie
Keytruda
Merck
Revlimid
Celgene
Opdivo
Bristol-Myers Squibb
Balm for Gilead: Unclean Hands Render Patents Unenforceable
JD Supra
Thu, 06/7/18 - 10:54 pm
Merck
Gilead Sciences
patents
hepatitis C
ASCO18: 3 unanswered questions from oncology's largest conference
Biopharma Dive
Thu, 06/7/18 - 09:35 am
ASCO 2018
Merck
Keytruda
Bristol-Myers Squibb
Opdivo
immunotherapy combinations
non-small cell lung cancer
ASCO18: Who were the big winners and losers?
Biopharma Dive
Wed, 06/6/18 - 04:06 pm
ASCO 2018
Merck
Loxo Oncology
Bluebird Bio
Celgene
Roche
Nektar
BIO18: Merck's Ebola lessons, New Jersey vies for biotech jobs
Biopharma Dive
Tue, 06/5/18 - 11:04 pm
Merck
ebola virus
New Jersey
biotech
BIO 2018
ASCO: Merck and its new multibillion-dollar partners hone plans for marketing onslaught
Fierce Pharma
Mon, 06/4/18 - 12:09 pm
Merck
ASCO 2018
Keytruda
AstraZeneca
Eisai
More Good News For Keytruda - Shows Promising Results in Patients with Advanced Small Cell Lung Cancer
CP Wire
Mon, 06/4/18 - 09:18 am
Merck
Keytruda
small cell lung cancer
ASCO 2018
More Good News For Keytruda - Shows Promising Results in Patients with Advanced Small Cell Lung Cancer
Mon, 06/4/18 - 09:12 am
Merck
Keytruda
small cell lung cancer
First Major Trial Of Keytruda For Prostate Cancer Shows It Works, But Only For A Minority Of Men
Forbes
Sun, 06/3/18 - 10:31 am
Merck
Keytruda
advanced prostate cancer
ASCO 2018
Merck's Keytruda shown to extend lung cancer survival in two trials
Reuters
Sun, 06/3/18 - 09:58 am
Merck
Keytruda
advanced squamous non-small cell lung cancer
ASCO 2018
Ahead of ASCO, BMS' Opdivo leads Merck's Keytruda in U.S. sales—but not for long, analyst predicts
Fierce Pharma
Fri, 06/1/18 - 11:49 am
ASCO 2018
Merck
Keytruda
Bristol-Myers Squibb
Opdivo
5 Best-Selling Orphan Drugs in the U.S.
Motley Fool
Wed, 05/30/18 - 09:13 pm
orphan drugs
Celgene
Revlimid
Roche
Rituxan
Teva Pharmaceutical
Copaxone
Opdivo
Bristol-Myers Squibb
Merck
Keytruda
With $460B in borrowing capacity, will any of the Big-20 biopharmas go after one of the top-5 takeover targets?
Endpoints
Tue, 05/29/18 - 09:22 pm
M&A
JNJ
Merck
Pfizer
Gilead Sciences
Amgen
Biogen
Takeda
Regeneron
Alexion
Roche’s Tecentriq scores again on a pivotal frontline lung cancer trial, positioning them against Merck, Bristol-Myers
Endpoints
Tue, 05/29/18 - 08:54 am
Roche
Tecentriq
anti-PD-L1
non-squamous non-small cell lung cancer
Merck
Bristol-Myers Squibb
FDA stalls Eisai—and its new partner Merck—in quest to widen cancer med Lenvima's reach
Fierce Pharma
Fri, 05/25/18 - 12:15 pm
Merck
Eisai
Lenvima
liver cancer
FDA
Cancer drug spending climbs, with top winners earning lion's share
Biopharma Dive
Fri, 05/25/18 - 10:04 am
drug spending
oncology
Merck
Bristol-Myers Squibb
Biopharma M&A: You Ain’t Seen Nothing Yet
Barron's
Fri, 05/25/18 - 09:32 am
JNJ
Merck
Pfizer
Gilead Sciences
Amgen
Regeneron
Alexion
M&A
Ahead of ASCO, Merck Touts Another Win for Lung Cancer Drug Combo
Xconomy
Wed, 05/23/18 - 10:01 am
Merck
Keytruda
advanced squamous non-small cell lung cancer
J&J, Pfizer, Merck again lead pharma in Fortune 500
Biopharma Dive
Tue, 05/22/18 - 06:04 pm
Fortune 500
Big Pharma
JNJ
Merck
Pfizer
FDA warns of decreased survival in 2 studies of Keytruda, Tecentriq
Biopharma Dive
Mon, 05/21/18 - 09:44 pm
FDA
clinical trials
oncologists
bladder cancer
Merck
Keytruda
Roche
Tecentriq

Pages